Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

cancer control

This page shows the latest cancer control news and features for those working in and with pharma, biotech and healthcare.

BMS’ Opdivo/Yervoy combination demonstrates OS benefit

BMS’ Opdivo/Yervoy combination demonstrates OS benefit

BMS’ Opdivo/Yervoy combination demonstrates OS benefit. Better kidney cancer symptom control reported versus sunitinib was also reported. ... Patients also reported a statistically significant better kidney cancer symptom control with the combination

Latest news

  • New guide to improve cancer control published in EU New guide to improve cancer control published in EU

    New guide to improve cancer control published in EU. Outlines recommendations to boost quality of life and reduce financial burden. ... A new guide aiming to save money, time and lives in the fight against cancer has been published by CanCon, the EU

  • FDA approves expanded indication for Gilotrif FDA approves expanded indication for Gilotrif

    FDA approves expanded indication for Gilotrif. US body gives Boehringer Ingelheim’ s oral lung cancer treatment the nod. ... Overall survival was improved by 19% with the once-daily oral form allowing patients greater control over their cancer symptoms

  • Boehringer's Giotrif wins new NSCLC licence in Europe Boehringer's Giotrif wins new NSCLC licence in Europe

    Boehringer Ingelheim's Giotrif (afatinib) has widened its European licence after regulators approved the drug for a type of non-small cell lung cancer (NSCLC). ... Overall survival was improved by 19% and allowed patients a better quality of life as well

  • AZ and BMS earn ASCO plaudits AZ and BMS earn ASCO plaudits

    AZ and BMS earn ASCO plaudits. Both firms tout new combination therapies at the annual cancer congress in Chicago. ... The combination of PD-L1 inhibitor MEDI4736 and tremelimumab - a CTLA4 inhibitor - showed clinical activity in patients with advanced

  • AZ pushes immuno-oncology duo into phase III AZ pushes immuno-oncology duo into phase III

    AZ pushes immuno-oncology duo into phase III. MEDI4736 and tremelimumab achieved disease control in 48% of NSCLC patients. ... The combination of PD-L1 inhibitor MEDI4736 and tremelimumab - a CTLA4 inhibitor - showed clinical activity in patients with

More from news
Approximately 1 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Avoiding data pitfalls in clinical research Avoiding data pitfalls in clinical research

    In a recent pilot study with Roche Pharmaceutical for a rare cancer indication, Medidata’s Synthetic Control Arm (SCA) pulled actual data from past studies to create well-matched control arms. ... The pilot was successful enough to be accepted for

  • Digital disruption Digital disruption

    Combining ‘drag and drop’computer simulations they’re trying to predict the best way to kill cancer cells with drugs that control their function. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.

  • Winning the war against cancer Winning the war against cancer

    At a regional cancer control meeting in Riga last month the Czech Republic, Slovenia and The Netherlands were held up as examples to learn from in areas such as centralised registries, ... its Health at a Glance publications and the European Union-funded

  • It’s time for pharma companies to become household names It’s time for pharma companies to become household names

    Pharma helps people survive heart attacks, beat cancer, manage depression and control diabetes, but until the companies behind these medicines become a visible part of people's lives, they're never

  • Country report: The healthcare market in South Korea Country report: The healthcare market in South Korea

    The leading cause of death is cancer, followed by cerebrovascular and heart disease. ... The R&D Program for Cancer Control funds research projects by industry, academia and research institutes.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • Immunotherapy in oncology

    This has led to major progress in disease control and prolonging the survival of cancer patients, but there are still major areas of unmet need. ... Three states of interaction exist in immunoediting;. Elimination, in which the immune response eradicates

  • World Cancer Day and the role of people-centred care

    Enabling patients to play an active role in decisions about their care and respecting their decisions can empower them to regain their sense of control throughout their cancer journey. ... Newsom T. How to cope with loss of control as a cancer patient.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Quick links

Infographics

Multimedia